J 2020

An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis

PELLETIER, J. P., J. P. RAYNAULD, M. DORAIS, L. BESSETTE, Eva DOKOUPILOVÁ et. al.

Basic information

Original name

An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis

Authors

PELLETIER, J. P., J. P. RAYNAULD, M. DORAIS, L. BESSETTE, Eva DOKOUPILOVÁ (203 Czech Republic, belonging to the institution), F. MORIN, K. PAVELKA, P. PAIEMENT and J. MARTEL-PELLETIER (guarantor)

Edition

RHEUMATOLOGY, OXFORD, OXFORD UNIV PRESS, 2020, 1462-0324

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 7.580

RIV identification code

RIV/00216224:14160/20:00118261

Organization unit

Faculty of Pharmacy

DOI

UT WoS

000606837500054

Keywords in English

diacerein; celecoxib; osteoarthritis; non-inferiority trial; SYSADOA

Tags

Tags

International impact, Reviewed
Změněno: 25/2/2021 08:18, Mgr. Hana Hurtová

Abstract

V originále

Objective. The objective of this study was to investigate whether diacerein has comparable efficacy with celecoxib in pain reduction for treatment in symptomatic knee OA patients. Methods. This randomized double-blind multicentre non-inferiority trial evaluated diacerein vs celecoxib treatment in patients with Kellgren-Lawrence grade 2-3 and pain scoring >= 4 (10-cm VAS). Patients were randomized to 6 months of treatment with diacerein 50 mg (n = 1 87) once daily for 1 month and twice daily thereafter, or celecoxib 200mg (n =193) once daily. The primary outcome was the change in WOMAC pain score (0-50 cm) at 6 months, and the secondary outcomes were WOMAC sub-scores, VAS pain score, and the OMERACT-OARSI responder rate. Results. In the per protocol population, the adjusted mean change from baseline in the WOMAC pain score was -11.1 (0.9) with diacerein (n = 1 40) and -11.8(0.9) with celecoxib (n = 1 48). The intergroup difference was 0.7 (95% CI: -1.8, 3.2; P = 0.597), meeting the non-inferiority margin. Supportive analysis of the intention-to-treat population gave similar results. Other outcomes showed no significant difference between treatment groups. The incidence of treatment-related adverse events was low and balanced between groups, but a greater incidence of diarrhoea occurred with diacerein (10.2% vs 3.7%). Diarrhoea was considered mild-to-moderate in all but one case with complete resolution. Conclusions. Diacerein was non-inferior to celecoxib in reducing knee OA pain and improving physical function. Diacerein also demonstrated a good safety profile.